Registry for Severe ROP and Treatment on Visual Outcomes
Study Registry for Severe Retinopathy and Treatment on Visual Outcomes of Premature Neonates
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Indiana
-
South Bend, Indiana, United States, 46601
- Memorial Hospital of South Bend
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Summerlin Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documentation of informed consent and authorization
- Inborn and those admitted within 7 days of birth
- Infant with a diagnosis of stage 2 ROP or higher
- Site ability to plan close ophthalmological follow-up due to significant and persistent ROP
- Parents must agree to report outcomes following each ophthalmological visit and overall outcomes for up to five (5) years of age
- Ability to obtain follow-up data on outcomes if the child is transferred to another facility
- No known major congenital anomalies
Exclusion Criteria:
- ROP stage 1 or less
- Parents unwilling to participate in follow-up
- Major congenital anomalies
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Identification of visual acuity in subjects who were treated for ROP
Time Frame: Five year follow-up
|
Five year follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence of stage 3+ retinopathy of prematurity in one or both eyes in zone I or posterior zone II Recurrence of stage 3+ retinopathy of prematurity in one or both eyes in zone I or posterior zone II
Time Frame: Five year follow-up
|
Five year follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Reese H Clark, MD, Mednax Center for Research, Education, Quality and Safety
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PDX-01-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.